Join Growin Stock Community!

Biodexa pharmaceuticals plcBDRX.US Overview

US StockHealthcare
(No presentation for BDRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BDRX AI Insights

BDRX Overall Performance

BDRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BDRX Recent Performance

-5.09%

Biodexa pharmaceuticals plc

0.05%

Avg of Sector

-0.31%

S&P500

BDRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BDRX Key Information

BDRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BDRX Profile

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Price of BDRX

BDRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BDRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-74.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.58
PB Ratio
0.06
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-12.76%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
2.76%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-74.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.58
PB Ratio
0.06
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-12.76%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
2.76%

  • When is BDRX's latest earnings report released?

    The most recent financial report for Biodexa pharmaceuticals plc (BDRX) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BDRX's short-term business performance and financial health. For the latest updates on BDRX's earnings releases, visit this page regularly.

  • How much cash does BDRX have?

    At the end of the period, Biodexa pharmaceuticals plc (BDRX) held Total Cash and Cash Equivalents of 4.04M, accounting for 0.27 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BDRX's EPS continuing to grow?

    According to the past four quarterly reports, Biodexa pharmaceuticals plc (BDRX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.51M. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BDRX?

    Biodexa pharmaceuticals plc (BDRX)'s Free Cash Flow (FCF) for the period is -3.31M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 31.23% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.